Media headlines about NewLink Genetics Corporation (NASDAQ:NLNK) have trended somewhat positive on Monday, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NewLink Genetics Corporation earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.8320139841394 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Benzinga’s Option Alert Recap From September 22 (feeds.benzinga.com)
- 3 Small-Cap Biotech Stocks to Buy This Fall (fool.com)
- ETFs with exposure to NewLink Genetics Corp. : September 19, 2017 (finance.yahoo.com)
- NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 (finance.yahoo.com)
A number of brokerages have recently issued reports on NLNK. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $26.00 price objective on shares of NewLink Genetics Corporation in a research report on Friday, September 8th. Stifel Nicolaus lifted their price objective on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. ValuEngine downgraded shares of NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Robert W. Baird raised shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $8.00 to $22.00 in a research report on Friday, September 8th. Finally, Jefferies Group LLC raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $7.00 to $26.00 in a research report on Friday, September 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. NewLink Genetics Corporation currently has an average rating of “Buy” and an average target price of $24.17.
NewLink Genetics Corporation (NASDAQ:NLNK) opened at 10.99 on Monday. The stock’s market cap is $323.34 million. NewLink Genetics Corporation has a 12 month low of $5.90 and a 12 month high of $25.17. The stock has a 50 day moving average of $8.77 and a 200-day moving average of $12.66.
NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The company had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. On average, equities analysts forecast that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/09/25/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-newlink-genetics-corporation-nlnk-stock-price.html.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.